This therapy may assist with managing the persistent discomfort and stiffness characteristic of conditions involving inflammatory or irritative processes, such as osteoarthritis. This class of treatment is applied across therapeutic domains involving localized symptomatic discomfort in the joint, primarily addressing mild to moderate osteoarthritis of the knee joint and shoulder periarthritis.

The treatment is applied in scenarios where additional management of discomfort is required, after initial therapies have failed to provide adequate symptomatic control. It provides supportive relief, which may help patients cope more steadily. It is applied in addressing conditions involving episodic or fluctuating manifestations, supporting patients who require localized symptomatic assistance. The therapy provides supportive relief that contributes to improved functional mobility, as it is considered relevant for managing symptoms that interfere with daily functioning, such as limited flexibility and restricted range of motion, which supports improved day-to-day comfort.

Quick Fact: Support for Joint Symptoms
Symptom Focus & Context	Chronic activity-related pain and mechanical joint stiffness in mild to moderate osteoarthritis
Use Scenario	Applied after initial therapies have failed to provide symptomatic relief
Patient Benefit	Provides supportive relief that contributes to improved functional mobility

The eligibility for Hyruan Plus, a viscosupplement injection, is strictly governed by regulatory documentation, which defines the patient populations who are permitted or restricted from using the product.

Official Eligibility and Contraindications

Classification	Rule Documented in Regulatory Labeling
Eligible Population	Adults with knee osteoarthritis who have failed to respond adequately to conservative therapies and simple analgesics (e.g., acetaminophen).
Absolute Contraindications	Patients with known hypersensitivity (allergy) to hyaluronate preparations.
Absolute Contraindications	Presence of infections or skin diseases in the area of the injection site or in the joint (to prevent septic arthritis).
Conditional Use	Patients with joint effusion must have the excess fluid removed before the injection.

Use Not Established in Special Populations

For certain groups, safety and effectiveness have not been formally established in regulatory studies, which limits or restricts use:

• Pediatric Patients: Use in children is not established.
• Pregnant Women: The safety and effectiveness of the injection in pregnant women have not been established.
• Lactating Mothers: It is not known if the drug is excreted in human milk, and safety has not been established.

The official interaction profile for intra-articular sodium hyaluronate, the active component of Hyruan Plus, is uniquely shaped by its localized route of administration and minimal systemic absorption. This leads to an absence of documented systemic drug-drug interactions, with the key restriction being a local chemical incompatibility.

Local Substance Incompatibility

The only interaction formally documented in regulatory prescribing information relates to a chemical reaction at the site of administration. Disinfectants containing quaternary ammonium salts (such as benzalkonium chloride) must not be used for skin preparation immediately prior to the injection. The official basis for this prohibition is that these specific salts cause the sodium hyaluronate solution to precipitate and lose its intended structure, which renders the product ineffective. This represents a mandatory constraint on the local administration procedure.

Absence of Systemic Interactions

Due to the localized injection into the joint space, regulatory documents do not report any clinically significant pharmacokinetic interactions involving metabolic enzymes (such as CYP enzymes) or drug transporters. Official labeling similarly reports no known pharmacodynamic interactions or interactions that significantly modify the systemic exposure (AUC/Cmax) of Hyruan Plus or any co-administered medicine. Furthermore, regulatory documentation specifies no formal interactions with food, alcohol, or herbal products.

How Hyruan Plus Works

Viscoelastic and Tribological Function

The sodium hyaluronate preparation exhibits high viscoelastic properties within the joint space. This physicochemical characteristic contributes directly to the boundary layer lubrication of articular cartilage, thereby modulating the friction coefficient between articulating joint surfaces during physiological movement.

Chondrocyte Receptor Binding and Matrix Synthesis

The Hyaluronate Acid (HA) component interacts with specific biological targets on the cellular level. Specifically, HA binds to receptors such as CD44 expressed on chondrocytes. This molecular interaction initiates intracellular signaling cascades that are integral to cartilage homeostasis and the synthesis of extracellular matrix components.

Regulation of Inflammatory Mediators

HA functions as a pathway modulator by interacting with inflammatory factors within the synovial fluid and membrane. It binds to inflammatory mediators, thereby regulating the expression of key pro-inflammatory cytokines, including IL-1beta and TNF-alpha.

Administration of Hyruan Plus (Sodium Hyaluronate)

Hyruan Plus is a viscosupplementation product, typically containing sodium hyaluronate at a concentration of 1% (20 mg in 2.0 mL), intended for the treatment of pain in patients with knee osteoarthritis who have failed to respond to conservative non-pharmacological therapies and simple analgesics. The administration is performed exclusively by a qualified healthcare professional.

Dosage and Injection Procedure

Administration involves a course of intra-articular injections into the affected knee joint. The recommended regimen is 2.0 mL once a week for three consecutive weeks. Prior to injection, the healthcare provider will prepare the site using aseptic technique to minimize the potential for developing septic arthritis, a rare but serious adverse event associated with intra-articular injections.

If excess joint fluid (effusion) is present, it may be aspirated (removed) before the injection to relieve pressure and swelling. The product is injected directly into the synovial space. After the injection, patients are generally advised to avoid strenuous activity such as jogging, heavy lifting, or prolonged standing for at least 48 hours.

Contraindications and Monitoring

Hyruan Plus must not be administered to patients with a known history of hypersensitivity or allergy to hyaluronate preparations. It is also contraindicated in cases of existing infections or skin diseases at the intended injection site. Patients should immediately report symptoms such as severe swelling, redness, fever, or pain that is disproportionate to what is expected, as these may indicate an injection-site reaction or infection.

Evidence for Use in Symptomatic Knee Osteoarthritis

Research for this viscosupplement product and its class was studied for adults with symptomatic knee osteoarthritis, particularly those whose condition is considered mild-to-moderate in severity. Studies were focused on patients who had not responded sufficiently to initial conservative treatments. The core research was studied for short-term symptom changes using Randomized Controlled Trials (RCTs). These trials research examined how patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level changed over time, comparing results to those seen in placebo groups.

Studies monitored findings describe patterns observed in the studies, including measurements of pain and function that varied across the study groups and control groups. These findings help contextualize how patients reported their experience during the specific, defined time intervals of the research.

---

Research Scope in Other Joints and Evidence Gaps

While the most detailed evidence was studied for the knee, research has also explored the viscosupplement class in conditions marked by functional limitations in other joints. Data for these joints remain insufficient in comparison to the evidence base available for the knee. For these related joints, the findings were mixed, and the certainty remains low.

The primary focus of most clinical trials was observed in short-term symptom patterns, with follow-up periods commonly assessed at 12 to 26 weeks. Long-term effects are not fully established, and the evidence is limited regarding patterns of change that extend beyond six months. Research has not yet definitively explored a relationship between the treatment and long-term outcomes, such as the need for joint replacement surgery. Furthermore, evidence quality varies across studies within the overall class, and subgroup findings are uncertain, meaning research does not determine whether an individual will respond similarly to the group patterns observed in the studies.

Key Studies & References

1. Hyaluronic acid injection therapy for osteoarthritis of the knee: concordant efficacy and conflicting serious adverse events in systematic reviews

Common questions about Hyruan Plus (FAQ)

Q: Is Hyruan Plus the same as other hyaluronic acid products?

Hyruan Plus is a specific brand of viscosupplement injection. According to official product information, it is characterized by its high molecular weight sodium hyaluronate, which sets it apart from other formulations within the same class of joint injections.

Q: How long do the effects of Hyruan Plus last?

Studies on this viscosupplement class commonly assess changes in symptoms and function over short-term follow-up periods, typically between 12 and 26 weeks. Official research summaries indicate that long-term effects beyond six months are not yet fully established.

Q: Can Hyruan Plus be used for pain other than in the knees?

The most detailed research evidence is available for use in the knee joint. While the viscosupplement class has been explored in other joints, official research reports state that the evidence base for these other joints remains insufficient compared to the data available for the knee.

Q: Is Hyruan Plus safe to use if I have an allergy to eggs?

According to product information, the active ingredient is highly purified, non-animal sourced sodium hyaluronate. The product is documented as being contraindicated in patients with a known history of hypersensitivity or allergy to hyaluronate preparations.

Q: Is Hyruan Plus considered a painkiller or a treatment?

Hyruan Plus is classified as a viscosupplement. This means it is a treatment intended to restore the joint's fluid properties, which then provides supplemental support for pain relief and improved joint mobility.

Q: What is the main difference between Hyruan Plus and standard hyaluronic acid injections?

The key features distinguishing the Hyruan Plus formulation include its high-molecular-weight structure and its derivation from a non-animal source. These characteristics contribute to its classification and intended stability within the joint.

Q: Can I take ibuprofen or Tylenol with Hyruan Plus?

Due to its localized injection into the joint space and minimal systemic absorption, regulatory documents report an absence of documented systemic drug-drug interactions.

Q: Why do some people need more than one course of Hyruan Plus?

Research evidence notes that patient response to viscosupplements can vary, and findings across different patient subgroups are uncertain. The medicine is indicated for use in individuals who have not responded adequately to initial non-pharmacological treatments.

Q: Are there any long-term side effects noted with Hyruan Plus use?

The most frequently documented side effects are local and generally transient, such as pain or swelling at the injection site. Official regulatory research has not fully established long-term effects beyond the typical 12-to-26 week follow-up periods assessed in clinical trials.

Q: Can Hyruan Plus interact with blood thinners like warfarin?

Regulatory documents report an absence of documented systemic drug-drug interactions due to the medicine's localized injection into the joint space and minimal systemic absorption. The only documented interaction is a local incompatibility with certain disinfectants.

Q: Is Hyruan Plus considered a biologic drug?

Hyruan Plus is classified as a viscosupplement. Its active ingredient is sodium hyaluronate, which is a linear polysaccharide, or a type of sugar molecule.

Q: Can older people use Hyruan Plus safely?

The product's eligible population is defined as adults with symptomatic knee osteoarthritis. Safety and effectiveness have not been formally established in certain special populations, such as pediatric or pregnant patients.

Q: What happens if a dose of Hyruan Plus is missed or delayed?

Adherence to the full recommended regimen is considered important for treatment outcomes. Regulatory class summaries indicate that appointments should be maintained, and if a treatment is missed or delayed, patients are often directed back to their administering healthcare professional for instruction.

Q: How does Hyruan Plus differ from steroid injections?

Hyruan Plus is a viscosupplement, not a steroid. Its mechanism of action involves increasing lubrication in the joint and modulating the friction coefficient, in addition to interacting with inflammatory factors. This differs from the primary anti-inflammatory mechanism of corticosteroids.

Q: Is Hyruan Plus approved in countries outside the US/Europe?

Official product information confirms that Hyruan Plus is manufactured by LG Chem and originates in South Korea. Details on specific approval status in individual international regions are typically not included in US or EU regulatory summaries.

Q: What kind of technology is used to make Hyruan Plus?

The product is made using highly purified, non-animal sourced sodium hyaluronate. The final formulation is designed to have a high molecular weight structure to support its intended viscoelastic properties within the joint.

Q: Do studies show Hyruan Plus works better than exercise therapy alone?

The medicine is indicated for use in patients who have failed to respond adequately to conservative non-pharmacological therapies, which includes non-pharmacological therapies like exercise. This is the criteria used by regulators to define the appropriate patient population.

Q: Can I drive after using Hyruan Plus?

Official administration advice includes avoiding strenuous activity for at least 48 hours following the injection. Because post-procedure guidance can vary, specific advice regarding activities like driving is determined by the administering healthcare professional.

Q: Can Hyruan Plus be used for problems in the hip joint?

The most detailed research evidence is available for use in the knee joint. While the viscosupplement class has been explored in other joints, official research reports state that the evidence base for these other joints remains insufficient compared to the data available for the knee.

Q: How is Hyruan Plus typically packaged?

Hyruan Plus is supplied as a sterile solution for injection. It is typically packaged in a pre-filled syringe designed for single-use administration by a healthcare professional.

Q: Are there any special warnings for people with liver or kidney issues when using Hyruan Plus?

Safety and effectiveness have not been formally established for Hyruan Plus in certain special populations, such as patients with severe liver or kidney issues. Because of this, the presence of such conditions is a factor that is taken into consideration by the administering healthcare professional.

Q: Do researchers know exactly how Hyruan Plus lubricates the joint?

The mechanism is described by its viscoelastic properties within the joint fluid. These properties are understood to contribute to boundary layer lubrication and the modulation of the friction coefficient between the articulating joint surfaces.

Q: What is the molecular weight of the hyaluronic acid in Hyruan Plus?

Regulatory and product information describe the sodium hyaluronate in this product as having a high molecular weight. This value is typically stated as around 3 million Daltons (3 MDa).

Q: Does Hyruan Plus help with joint stiffness?

The general therapeutic purpose is to address joint function by improving the mobility of affected joints. This is achieved by reducing the detrimental friction between cartilage surfaces.

Q: Do different brands of hyaluronic acid injections have different safety profiles?

Research studies have examined the potential for differences across the various brands and formulations within the viscosupplement class. These studies explore how factors like molecular weight and manufacturing may affect the safety and efficacy profiles.

Q: Can Hyruan Plus be used repeatedly over many years?

Research has focused primarily on short-term symptom patterns, with evidence limited regarding changes that extend beyond six months. Official regulatory summaries indicate that long-term effects and the patterns of repeated use over many years are not fully established.

Q: Is there a generic version of Hyruan Plus available?

Hyruan Plus is a specific brand-name product within the sodium hyaluronate class. The availability of a generic alternative for this specific formulation may depend on the regulatory classification in different countries.

Hyruan Plus injection must be stored strictly according to its regulatory requirements to maintain product integrity and stability. The official label mandates that the medicine be stored in a refrigerator at a temperature range of 2 C to 8 C.

Storage and Handling

Condition	Requirement
Temperature	Store in a refrigerator (2 C to 8 C).
Prohibited	Do not freeze the product.
Protection	Must be protected from light and kept in a hermetic container.
Child Safety	Store out of the sight and reach of children and pets.

Disposal Instructions

Since the pre-filled syringe is intended for single use, any unused or expired portion of Hyruan Plus must be discarded after administration. Disposal of the unused medicine or waste material must be carried out in accordance with local regulatory requirements for pharmaceutical waste.